



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/508731/2014

European Medicines Agency decision

P/0244/2014

of 29 September 2014

on the acceptance of a modification of an agreed paediatric investigation plan for metformin (hydrochloride) (EMEA-001352-PIP01-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0244/2014

of 29 September 2014

on the acceptance of a modification of an agreed paediatric investigation plan for metformin (hydrochloride) (EMA-001352-PIP01-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0147/2013 issued on 3 July 2013,

Having regard to the application submitted by EffRx Pharmaceuticals SA on 26 May 2014 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 August 2014, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for metformin (hydrochloride), effervescent granules, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to EffRx Pharmaceuticals SA, Wolleraustrasse 41B, 8807 - Freienbach, Switzerland.

Done at London, 29 September 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/327826/2014

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-001352-PIP01-12-M01

Scope of the application

Active substance(s):

Metformin (hydrochloride)

Condition(s):

Treatment of polycystic ovary syndrome

Pharmaceutical form(s):

Effervescent granules

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

EffRx Pharmaceuticals SA

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, EffRx Pharmaceuticals SA submitted to the European Medicines Agency on 26 May 2014 an application for modification of the agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/0147/2013 issued on 3 July 2013.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 18 June 2014.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.



Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 15 August 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of polycystic ovary syndrome

The waiver applies to:

- boys from birth to less than 18 years and premenarcheal girls;
- for effervescent granules, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets.

And to:

- postmenarcheal girls less than 2 years post-menarche or below 14 years of age for girls with primary amenorrhea;
- for effervescent granules, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subsets.

2. Paediatric Investigation Plan

2.1. Condition: treatment of polycystic ovary syndrome

2.1.1. Indication(s) targeted by the PIP

Treatment of polycystic ovary syndrome as adjunct to diet and exercise in adolescent girls to improve menstrual regularity and insulin resistance

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

Girls from 2 years post-menarche or from 14 years of age for patients with primary amenorrhea to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Effervescent granules

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1: Development of new pharmaceutical form for use in the paediatric population: effervescent granules for oral use.

Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 3: Randomized, double-blind, placebo-controlled trial to determine the safety and efficacy of metformin on improvement of menstruation cycle regularity in adolescent girls from 2 years post-menarche to less than 18 years of age with Polycystic Ovary Syndrome.
Extrapolation, modelling and simulation studies	1	Study 2: Population based pharmacokinetic modelling and simulation approach of metformin PK data from published data in adults and adolescents to girls from 2 years post-menarche to less than 18 years of age with Polycystic Ovary Syndrome.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By November 2016
Deferral for one or more measures contained in the paediatric investigation plan:	No